Back to search
Metastatic Testicular Cancer
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Metastatic Testicular Cancer trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Metastatic Testicular Cancer trials you may qualify forThis phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors th…
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimens…
This phase I trial evaluates whether adding Pedmark to standard of care cisplatin-based chemotherapy reduces drug-induced ear damage (ototoxicity) in men with s…
This study evaluates the accuracy of blood-based biomarker testing to predict the presence of active testicular cancer.
Testicular germ cell tumor (TGCT) is the most common malignancy in men between 15 and 40 years. Although TCGT survivors have a good survival prognosis, they suf…
The goal of this prospective observational study is to learn about the short- and long-term effects of treating men over the age of 18 with good prognosis metas…
This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipil…
To evaluate the feasibility of introducing a men's cancer survivorship programme into routine follow up care in patients with advanced genitourinary malignancie…
This phase I trial studies the side effects and the best dose of veliparib when given together with paclitaxel and carboplatin in treating patients with solid t…